Background {#Sec1}
==========

*Epidermal growth factor receptor* (*EGFR*)-tyrosine kinase inhibitor (TKI) is the recommended first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring somatic driver mutation in the *EGFR* gene \[[@CR1]\]. Several phase III clinical trials have reported promising median progression-free survivals (mPFS) (9--13 months) and tolerable side-effects in patients with *EGFR*-mutant advanced NSCLC receiving first-generation *EGFR*-TKIs \[[@CR2]--[@CR6]\].

Afatinib is an irreversible, second-generation *EGFR*-TKI that has been shown to be more potent than platinum doublet chemotherapies as well as the first-generation *EGFR*-TKIs, such as gefitinib and erlotinib \[[@CR7]--[@CR10]\]. In the LUX-Lung 7 study, patients receiving first-line afatinib for *EGFR* mutant advanced NSCLC had significantly longer mPFS and median time-to-treatment failure than those on first-line gefitinib \[[@CR9]\]. In LUX-Lung 8, patients receiving second-line afatinib for advanced squamous cell carcinoma of lung had significantly longer mPFS and median overall survival (mOS) than those on second-line erlotinib \[[@CR10]\]. Since afatinib targets all homo-dimers and hetero-dimers of the ErbB family (*EGFR*/ErbB1, *HER2*/ErbB2, ErbB3, and ErbB4), it is more efficacious than first-generation *EGFR*-TKIs \[[@CR11], [@CR12]\]. At the same time, the broad spectrum of activity and irreversible mechanism of action of afatinib also lead to more treatment related side-effects.

Patients with rare or complex *EGFR* mutation, symptomatic brain metastases, poor Eastern Cooperative Oncology Group (ECOG) performance status and inadequate organ function are routinely excluded from clinical trials. Nevertheless, these unfavourable characteristics are commonly encountered in clinical practice. Therefore, this study aimed to look into the efficacy and side-effects of first-line afatinib in the real-world setting. In addition, the mechanisms of acquired resistance causing first-line afatinib failure were analyzed.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

This is a multicenter observational study of Malaysian patients with *EGFR-*mutant advanced NSCLC started on first-line afatinib treatment at the University of Malaya Medical Center, Subang Jaya Medical Center, Beacon International Specialist Hospital, Pantai Hospital Kuala Lumpur, Gleneagles Hospital Penang and Hospital Tengku Ampuan Afzan Kuantan from 1st October 2014 to 30th April 2018. All patients analyzed were aged 18 years and above, had histologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) NSCLC and had *EGFR* mutation detected in the pre-treatment biopsy specimens. Patients were excluded if they had previous cytotoxic chemotherapy or targeted therapy. Patients with symptomatic brain metastases and inadequate organ function were not excluded. The study was approved by the ethics committees of the respective hospitals that also granted an informed consent waiver.

Procedure {#Sec4}
---------

Eligible patients were retrospectively identified from the lung cancer databases and pharmacy dispensing records of the respective hospitals. The patients' demographic, clinical, and treatment data, as well as resistance mechanisms to afatinib were extracted from their case records. A never smoker was defined as one with lifetime cigarette smoking of less than 100 sticks \[[@CR13]\]. The patients' organ function at diagnosis was graded according to Common Terminology Criteria for Adverse Events version 4 (CTCAE v4.0) for blood, renal and liver function \[[@CR14]\]. Initial tumor biopsy specimens of the patients were tested for *EGFR* mutations using the cobas® *EGFR* Mutation Test v2 (Roche Molecular Systems, New Jersey, USA), or peptic nucleic acid-locked nucleic acid polymerase chain reaction (PCR) clamp method, PNAClamp™ *EGFR* Mutation Detection Kit (PANAGEN, Daejon, Korea). Baseline computed tomography (CT) examination of the thorax, abdomen and pelvis (TAP) was performed in every patient at diagnosis. CT-brain was performed in those with neurological symptoms or signs. The patient's NSCLC was staged according to the 7th edition of the American Joint Committee on Cancer \[[@CR15]\]. Tumor response was evaluated by performing a repeat CT-TAP 4 weeks after the initiation of afatinib, and subsequently, once every 12 weeks until disease progression or symptomatic deterioration, whichever occurred earlier. Tumor response was categorized according to the Response Evaluation Criteria in Solid Tumors version 1.1 \[[@CR16]\].

Patients received afatinib at starting doses of 40 mg, 30 mg, 25 mg or 20 mg once daily. Afatinib 40 mg once daily is the recommended starting dose. Afatinib at 30 mg once daily was only started in patients with *exon 19* deletion or *exon 21 L858R* point mutation who did not have symptomatic brain metastases. Afatinib 20 mg once daily and 25 mg once daily were derived by dividing the 40 mg and 50 mg tablets into halves, respectively. These adjusted dosages were only given to patients who were financially constrained to self-purchase the drug. The maintenance dose of afatinib ranged from 20 to 50 mg once daily depending on the patients' clinical response and tolerability. The optimum dose of afatinib was defined as the dose that could control the patient's disease alongside tolerable side-effects for the patient. Afatinib was given until symptomatic disease progression or occurrence of intolerable side-effects. Only common side-effects documented during clinic visits such as diarrhea, stomatitis, skin rash, acne, paronychia and fatigue were assessed and graded according to CTCAE v4.0 \[[@CR14]\]. Second-line treatment was offered when patients experienced symptomatic disease progression confirmed by CT scan or intolerable side-effects from afatinib. At any time, patients with symptomatic brain metastases were offered surgical resection, whole brain radiotherapy or stereotactic radiotherapy for brain lesions based on the decision of the multidisciplinary team in the respective centers.

Investigations for acquired *exon 20 T790 M* mutation and histological transformation were only performed in patients who had PD after 31st December 2015 when early access to the third-generation *EGFR*-TKI, osimertinib became available. Investigation for *T790 M* mutation involved tissue re-biopsy or liquid biopsy. The former utilized the similar *EGFR* mutation detection technique as at initial diagnosis; while for the latter peptic nucleic acid-locked nucleic acid polymerase chain reaction (PCR) clamp method (PANAGEN, Daejon, Korea) or p-*EGFR* droplet digital PCR-based technology (Sanomics, Hong Kong, China) was used.

Statistical analysis {#Sec5}
--------------------

Categorical variables were expressed as percentages while continuous variables were expressed as mean ± standard deviation (SD) or median with range depending on the normality of distribution of the variables. Kaplan-Meier methodology was used to determine the mPFS and mOS. Differences between categorical variables were tested using Chi-Squared test or Fisher Exact test. For continuous variables, the differences were compared using independent t-test or Mann-Whitney U test. Multivariate analysis was performed using logistic regression. A p-value of \< 0.05 was considered statistically significant. Statistical analyses were performed by using the software package, Statistical Package for the Social Sciences (SPSS for Windows version 23.0, SPSS Inc., Chicago, IL, USA).

Results {#Sec6}
=======

Demographic and clinical characteristics {#Sec7}
----------------------------------------

A total of 85 patients who met the study criteria were included (Fig. [1](#Fig1){ref-type="fig"}). Their demographic and clinical characteristics are shown in Table [1](#Tab1){ref-type="table"}. The majority of the patients were female, never smokers and of Chinese ethnicity. Eighty-two (96.5%) patients had lung adenocarcinoma while the remaining had squamous cell carcinoma. The *EGFR* mutations harbored by the tumors included *exon 19* deletion in 80.0%, *exon 21 L858R* point mutation in 12.9%, and rare or complex *EGFR* mutations in 7.1% of the patients. The ECOG performance status was 2--4 in 18.8%, symptomatic baseline brain metastases were present in 29.4%, and abnormal organ function at baseline was present in 17.6% of the patients. Fig. 1Flow of patient selection according to inclusion criteria Table 1Demographic and clinical characteristics of patientsDemographic and clinical characteristicNo. of patients\
(*n* = 85)Age, year Mean (+ SD)59.1 + 10.8Gender, No. (%) Female47 (55.3) Male38 (44.7)Ethnicity, No. (%) Chinese63 (74.1) Non-Chinese (Malay and Indian)22 (25.9)Smoking history, No. (%) Never smoker67 (78.8) Previous or current smoker18 (21.2)ECOG performance status at diagnosis, No. (%) ECOG 0--169 (81.2) ECOG 2--416 (18.8)Tumor histology, No. (%) Adenocarcinoma82 (96.5) Squamous cell carcinoma3 (3.5)Tumor stage, No. (%) IIIB4 (4.7) IV81 (95.3)Symptomatic baseline brain metastases, No. (%) No60 (70.6) Yes25 (29.4)  -Parenchymal metastases16 (64.0)  -Leptomeningeal metastases7 (28.0)  -Both parenchymal and leptomeningeal metastases2 (8.0)Abnormal organ function, No. (%) No70 (82.4) Yes15 (17.6)  -Blood5 (33.3)  -Renal9 (60.0)  -Liver2 (13.3)*EGFR* mutation subtype, No. (%) *Exon 19* deletion68 (80.0) E*xon 21 L858R* point mutation11 (12.9) Rare or complex mutations6 (7.1)  -*Exon 18 G719X*2 (33.1)  -*Exon 18 G71*9X and *exon 20 S768I*1 (16.7)  -*Exon 18 G719X* and *exon 20 T790 M*1 (16.7)  -*Exon 19* deletion and *exon 20 insertion*1 (16.7)  -*Exon 20* insertion1 (16.7)*Abbreviations*: *ECOG* Eastern Cooperative Oncology Group, *EGFR epidermal growth factor receptor*

Afatinib starting dose, dose adjustment and optimal dose and treatment of baseline brain metastases {#Sec8}
---------------------------------------------------------------------------------------------------

Most of the patients were started on afatinib 40 mg once daily (52.9%), followed by 30 mg once daily (35.3%), 20 mg once daily (8.2%) and 25 mg once daily (3.5%) (Table [2](#Tab2){ref-type="table"}). The initial starting dose of afatinib could be maintained in more than half of the patients. Afatinib dose reduction was exclusively due to side-effects while dose escalation was because of inadequate treatment response. The optimum dose of afatinib was 40 mg once daily or 30 mg once daily in 35.7 and 35.7% of the patients, respectively. Of the 25 patients with baseline symptomatic brain metastases, 21 (84.0%) had brain radiotherapy or surgical resection of the brain lesions on top of the first-line afatinib (Table [2](#Tab2){ref-type="table"}). Table 2Afatinib starting dose, dose adjustment and optimal dose and treatment of baseline brain metastasesTreatment Pattern and OutcomeTotal number of patients\
(*n* = 85)Afatinib starting dose, No. (%) 40 mg once daily45 (52.9) 30 mg once daily30 (35.3) 25 mg once daily3 (3.5) 20 mg once daily7 (8.2)Afatinib dose adjustment, No. (%) Starting dose maintained49 (57.6) Dose increased10 (11.8) Dose reduced26 (30.6)Afatinib optimum dose, No. (%) 50 mg once daily4 (4.7) 40 mg once daily30 (35.3) 30 mg once daily30 (35.3) 25 mg once daily12 (14.1) 20 mg once daily9 (10.6)Brain metastasis treatment, No. (%) No brain metastases60 (70.6) Afatinib alone4 (4.7) Afatinib with surgery or radiotherapy21 (24.7)

Treatment outcome {#Sec9}
-----------------

### Response to afatinib {#Sec10}

The objective response rate (ORR) was 76.5% while the disease control rate (DCR) was 95.3% on first-line afatinib (Table [3](#Tab3){ref-type="table"}). Two (2.4%) patients had complete response. The ORR and DCR according to *EGFR* mutation subtype, presence or absence of symptomatic brain metastases, ECOG performance status, presence or absence of abnormal organ function, afatinib dose adjustment and different optimal doses of afatinib are shown in Table [4](#Tab4){ref-type="table"}. Patients without baseline symptomatic brain metastases had significantly better response to afatinib than those with symptomatic baseline brain metastases (81.7 versus 56.0%, *p* = 0014). On multivariate subgroup analyses involving the covariates as shown in Table [4](#Tab4){ref-type="table"}, patients without symptomatic brain metastases had significantly higher ORR than that of those with symptomatic brain metastases (81.7 versus 56.0%; OR, 4.51; 95% CI, 1.45--14.00; p = 0.009); while patients with afatinib dose reduction had significantly higher ORR than that of those without dose adjustment (88.5 versus 65.3%, OR, 5.53; 95% CI, 1.32--23.24; *p* = 0.019). Table 3Treatment outcome to afatinib and resistance mechanism identified at disease progressionTreatment outcomeTotal number of patients\
(*n* = 85)Best tumor response, No. (%) Complete response2 (2.4) Partial response63 (74.1) Stable disease16 (18.8) Progressive disease4 (4.7)Disease progression site, No. (%) None29 (34.1) New brain lesions7 (8.2) New lesions at other sites49 (57.6)Investigation for resistance mechanism, No. (%) No progression29 (34.1) Not investigated25 (29.4) Investigated31 (36.5)  -*Exon 20 T790 M* mutation detected13 (42.0)  -*Exon 20 T790 M* mutation not detected and no histologic transformation18 (58.0) Table 4Univariate and multivariate analyses of ORR and DCR according to clinical and treatment characteristicsCharacteristicsORR, No. (%)^\*^*p*-value^g^OR (95% CI), *p*-valueDCR, No. (%)^\*^*p*-value^g^OR (95% CI), *p*-value*EGFR* mutation subtype, No. (%) *Exon 19* deletion52 (76.5)0.2652.27 (0.47--11.01), 0.309^a^64 (94.1)0.2632.72 (0.41--18.24), 0.302^a^ *Exon 21 L858R* point mutation6 (54.5)0.40 (0.03--5.21), 0.485^b^9 (81.8)2.28 (0.31--16.62), 0.420^b^ Rare and complex mutation5 (83.3)6 (100)Baseline symptomatic brain metastases, No. (%) No49 (81.7)0.0144.51 (1.45--14.00), 0.009^\#^57 (95.0)0.2513.0 (0.55--16.38), 0.205^\#^ Yes14 (56.0)22 (88.0)ECOG performance status, No. (%) 0--149 (71.0)0.1750.27 (0.05--1.44), 0.125^\#^64 (92.8)0.8890.79 (0.08--8.76), 0.835^\#^ 2--414 (87.5)15 (93.8)Abnormal organ function, No. (%) No53 (75.7)0.4681.27 (0.28--5.81), 0.755^\#^64 (91.4)0.5850.57 (0.07--4.97), 0.616 ^\#^ Yes10 (66.7)15 (100)Afatinib dose adjustment, No. (%) Dose reduced23 (88.5)0.0845.53 (1.32--23.24), 0.019^c^25 (96.2)0.7293.22 (0.29--35.40), 0.339^c^ Dose increased8 (80.0)2.13 (0.36--12.57), 0.404^d^9 (90.0)1.30 (0.11--15.02), 0.835^d^ Starting dose maintained32 (65.3)45 (91.8)Optimal afatinib dose, No. (%) Less than 40 mg once daily40 (78.4)0.1562.03 (0.59--6.94), 0.259^e^47 (92.2)0.8360.88; 0.13--6.13, 0.895^e^ 40 mg once daily19 (63.3)28 (29.3) 50 mg once daily4 (100)^f^4 (100)^f^*Abbreviations*: *ORR* objective response rate, *DCR* disease control rate, *OR* odd ratio, *95% CI* 95% confidence interval, *EGFR epidermal growth factor receptor, ECOG* Eastern Cooperative Oncology Group\**p*-value of Chi-square test^\#^second parameter was the reference group^a^*exon 19* deletion versus *exon 21 L858R* point mutation; ^b^*exon 19* deletion versus rare and complex mutations^c^afatinib dose reduced versus starting dose maintained; ^d^afatinib dose increased versus starting dose maintained^e^afatinib less than 40 mg once daily versus 40 mg once daily^f^afatinib dose 50 mg once daily not compared because of the small number of patients^g^multivariate analysis with cox regression

### Progression-free survival {#Sec11}

The mPFS was 14.2 months (95% CI, 11.85--16.55 months) with 56 (65.9%) patients having PD at the time of analysis (Fig. [2](#Fig2){ref-type="fig"}). Only 12.5% of patients with PD experienced new symptomatic brain metastases while the remaining had PD at new sites other than the brain. The mPFS according to *EGFR* mutation subtype, presence or absence of symptomatic brain metastases, ECOG performance status, presence or absence of abnormal organ function, afatinib dose adjustment and different optimal doses of afatinib are shown in Table [5](#Tab5){ref-type="table"}. On univariate analysis, only patients with *exon 19* deletion had significantly longer mPFS compared to patients with *exon 21 L858R* point mutation (16.0 versus 8.7 months; HR, 0.31; 95% CI, 0.14--0.71; p = 0.006) and rare or complex *EGFR* mutations (16.0 versus 9.0 months; HR, 0.34; 95% CI, 0.13--0.94, *p* = 0.037). On multivariate analysis, only the mPFS of patients with *exon 19* deletion was significantly longer than the mPFS of patients with *exon 21 L858R* point mutation (16.0 versus 8.7 months; HR, 0.27; 95% CI, 0.12--0.58; *p* = 0.001). Fig. 2Kaplan-Meir plot for progression-free survival of patients on first-line afatinib Table 5Univariate and multivariate analyses of progression-free survival according to clinical and treatment characteristicsCharacteristicsPatients, No. (%)mPFS (months)Univariate analysisMultivariate analysisHR (95% CI)*p*-valueHR (95% CI)*p*-value*EGFR* mutation subtype, No. (%) *Exon 19* deletion68 (80.0)16.00.31 (0.14--0.71)^a^0.0060.27 (0.12--0.58)^a^0.001 *Exon 21 L858R* point mutation11 (12.9)8.70.34 (0.13--0.94)^b^0.0370.39 (0.15--1.03)^b^0.058 Rare and complex mutation6 (7.1)9.0Baseline symptomatic brain metastases, No. (%) No60 (70.6)14.30.67 (0.34--1.27)^g^0.2090.70 (0.37--1.32)^g^0.267 Yes25 (29.4)13.5ECOG performance status, No. (%) 0--169 (81.2)13.80.86 (0.39--1.90)^g^0.7030.86 (0.39--1.90)^g^0.703 2--416 (18.8)15.9Abnormal organ function, No. (%) No70 (82.4)14.30.53 (0.25--1.09)^g^0.0860.50 (0.25--1.00)^g^0.050 Yes15 (17.6)8.8Afatinib dose adjustment, No. (%) Dose reduced26 (30.6)15.90.93 (0.44--1.99)^c^0.8540.72 (0.39--1.34)^c^0.301 Dose increased10 (11.8)13.52.35 (0.86--6.47)^d^0.0982.13 (0.93--4.88)^d^0.075 Starting dose maintained49 (57.6)13.4Optimal afatinib dose, No. (%) Less than 40 mg once daily51 (60.0)15.90.64 (0.32--1.28)^e^0.2090.47 (0.21--1.08)^e^0.075 50 mg once daily4 (4.7)13.50.97 (0.25--3.78)^f^0.9621.03 (0.27--4.01)^f^0.962 40 mg once daily30 (35.3)13.4*Abbreviations*: *PFS* progression-free survival, *mPFS* median PFS, *HR* hazard ratio, *95% CI* 95% confidence interval, *EGFR epidermal growth factor receptor, ECOG* Eastern Cooperative Oncology Group^a^*exon 19* deletion versus *exon 21 L858R* point mutation; ^b^*exon 19* deletion versus rare and complex mutations^c^afatinib dose reduced versus starting dose maintained; ^d^afatinib dose increased versus starting dose maintained^e^afatinib less than 40 mg once daily versus 40 mg once daily; ^f^afatinib 50 mg once daily versus 40 mg once daily^g^the second group was the reference category in logistic regression analysis

### Overall survival {#Sec12}

The mOS was 28.9 months (95% CI, 19.82--37.99 months) (Fig. [3](#Fig3){ref-type="fig"}). Thirty-three (38.8%) patients had died at the time of analysis while the median follow-up period for the survivors was 20.0 months (95% CI, 17.49--22.51 months). Fig. 3Kaplan-Meir plot for overall survival of patients on first-line afatinib

Resistance to afatinib {#Sec13}
----------------------

Of 56 patients who experienced PD while on afatinib, only 31 (55.4%) had PD after 31st December 2015 and were investigated for resistance mechanisms (Table [3](#Tab3){ref-type="table"}). *Exon 20 T790 M* mutation was detected in 42.0% of the 31 patients, while no resistance mechanism could be identified in the remaining 58.0%. *T790 M* mutation was detected exclusively in lung adenocarcinoma and was more frequent in female patients (47.1% versus 35.7%, *p* = 0.524).

Side-effects of afatinib treatment {#Sec14}
----------------------------------

One-fifth of the patients did not experience any side-effect; while one-tenth of patients experienced severe side-effects while taking afatinib (Table [6](#Tab6){ref-type="table"}). None of the patients had grade 4 side-effects. Acne (70.6%) was the most common side-effect, followed by diarrhea (54.1%), paronychia (40.0%), stomatitis (27.1%) and fatigue (16.5%). Table 6Side-effects of first-line afatinibCTCAE gradeGrade 0Grade 1Grade 2Grade 3Grade 4Diarrhea, No. (%)39 (45.9)25 (29.4)17 (20.0)4 (4.7)0Stomatitis, No. (%)62 (72.9)13 (15.3)8 (9.4)2 (2.4)0Acne/rash, No. (%)25 (29.4)35 (41.2)20 (23.5)5 (5.9)0Paronychia, No. (%)51 (60.0)23 (27.1)8 (9.4)3 (3.5)0Fatigue, No. (%)71 (83.5)13 (15.3)1 (1.2)00Side-effects, No (%)17 (20.0)59 (69.4)9 (10.6)*Abbreviations*: *CTCAE* Common Terminology Criteria for Adverse Events

Discussion {#Sec15}
==========

In this study, patients with *exon 19* deletion had significantly longer mPFS than those with *exon 21 L858R* point mutation. Most of the patients with rare or complex *EGFR* mutations demonstrated response to afatinib despite a shorter PFS than that of those with *exon 19* deletion. On the other hand, patients with baseline symptomatic brain metastases did not have significantly shorter PFS compared to those without baseline symptomatic brain metastases despite their lower response rate to afatinib. Other unfavorable clinical characteristics frequently encountered in real-world practice such as poor ECOG performance status or abnormal organ function did not significantly affect the response rate to afatinib or PFS, which implies that afatinib works well even in these patients. Afatinib 40 or 30 mg once daily seems to be the optimal maintenance dose which is effective for Malaysian patients and are uncommonly associated with severe side-effects. The need for dose reduction due to side-effects and the ability of the reduced dose to control the disease are reassuring to the treating clinicians. Symptomatic brain metastases causing failure to first-line afatinib were uncommon and acquired *T790 M* mutation is the most common identified resistance mechanism.

The demographic characteristics of our patients were consistent with previous reports, in which females, never smokers and Asians of Chinese ethnicity were predominant \[[@CR17]--[@CR19]\]. The majority of our patients harbored *exon 19* deletion. This could have been due to selection bias whereby the treating clinicians were influenced by the mOS result of the LUX-Lung 3 and LUX-Lung 6 studies which favored first-line afatinib over cytotoxic chemotherapy among patients with *exon 19* deletion \[[@CR7], [@CR8], [@CR20]\]. The mPFS and ORR of patients receiving first-line afatinib in the present study correspond to that reported in randomized control trials (RCTs) (11.0--11.1 months; 56.0--70.0%) and other real-world studies (11.8--11.9 months; 67.2--78.4%) \[[@CR7]--[@CR9], [@CR21]--[@CR24]\]. Another two real-world studies by Wu et al. \[[@CR25]\] and Kim et al. \[[@CR26]\] however, reported a much longer mPFS (21.0 and 19.1 months, respectively) among their patients receiving first-line afatinib. The former study included 14 patients who achieved a partial response or at least 6 months of stable disease when on first-line afatinib while the latter study only involved patients with ECOG 0--2 which could have contributed to the longer mPFS. Similar to the present study, Liang et al. \[[@CR21]\], Tan et al. \[[@CR22]\] Kim et al. \[[@CR26]\] and Tanaka et al. \[[@CR24]\] also consistently highlighted a longer mPFS and better ORR in patients with tumors harboring *exon 19* deletion treated with first-line afatinib compared to those with *exon 21 L858R* point mutation. In patients with complex or rare *EGFR* mutations treated with first-line afatinib, the present study and another three real-world studies reported a modest mPFS and ORR \[[@CR21], [@CR22], [@CR27]\]. Similar beneficial response was not seen in such patients treated with first-generation *EGFR*-TKIs \[[@CR27]\]. Contrary to the findings by Tan et al. \[[@CR22]\], the present study did not find a significantly shorter mPFS among patients with symptomatic brain metastases receiving first-line afatinib \[[@CR22]\]. This favorable outcome could be explained by the uniform afatinib starting dose of 40 mg once daily and the comprehensive brain surgery or radiotherapy approach in the present study cohort. On the other hand, the findings of no difference in the survival and response rate among patients without symptomatic brain metastases when given afatinib 40 mg or less than 40 mg once daily in other studies are also in agreement with the present study \[[@CR21], [@CR23]\]. In a recent study by Hochmair et al. \[[@CR28]\], *exon 19* deletion, absence of active brain metastases and good ECOG performance status were shown to be associated with longer initial and post-progression treatment duration in a cohort of patients who developed *T790 M* mutation following first-line afatinib treatment and subsequently treated with osimertinib. The median treatment duration for subgroups of patients with active brain metastases or poor ECOG performance status on first-line afatinib was 10.4 months in that study.

The present study and other real-world studies report a much lower incidence of grade 3 or 4 afatinib side-effects when compared to the incidence of 36.0--57.0% reported by RCTs \[[@CR7]--[@CR9], [@CR21]--[@CR23], [@CR26]\]. This could have been due to the lower afatinib starting dose among patients without symptomatic brain metastases and rare or complex *EGFR* mutations in real-world studies. Early dose de-escalation in some patients before developing grade 3 side-effects in real-world practice could be another explanation. Nevertheless, the retrospective nature of these real-world studies could be a confounding factor for under reporting of drug side-effects. Upon PD on first-line afatinib, the incidence of new brain metastases in the present study was lower than that reported by Liang et al. \[[@CR21]\] and Campo et al. \[[@CR29]\] (18.6--19.0%). The incidence of acquired *T790 M* mutation was comparable to that reported in the literature (32.1--47.6%) but less than that reported in studies involving first-generation *EGFR*-TKIs (49.0--63.0%) \[[@CR21], [@CR24]--[@CR26], [@CR30]--[@CR33]\].

This study is among the very few real-world analyses that include patients with unfavorable characteristics such as rare or complex *EGFR* mutations, symptomatic brain metastases, poor ECOG performance status and inadequate organ function. These characteristics have been routinely excluded in RCTs but are common challenges in the real-world. The result of our study therefore further complements the existing information on afatinib from RCTs. Another strength of our study is that we attempted to explore the efficacy of afatinib in various doses and highlight the non-inferior response among patients with symptomatic brain metastases on afatinib 40 mg once daily.

This study has several limitations. Its retrospective nature might have led to possible errors in data recording or measurement. The number of patients with *exon 21 L858R* point mutation was disproportionately small. Only about half of the patients with PD were investigated for acquired resistance which was limited to *T790 M* mutation and histologic transformation. Fatigue is a subjective symptom which could have been underreported by the patients during clinic visits.

Conclusions {#Sec16}
===========

Afatinib is an effective first-line treatment for patients with *EGFR*-mutant NSCLC. It is associated with good response rate and prolonged PFS. Patients with unfavorable clinical characteristics such as rare or complex *EGFR* mutations, symptomatic brain metastases, poor ECOG performance status, and inadequate organ function also benefit from first-line afatinib treatment. The side-effects of afatinib are moderate and *T790 M* mutation is the most common resistance mechanism identified.
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